Business Context and Reporting Period
This Form 8-K Current Report from Clover Health Investments, Corp. (CLOV) covers the date of March 30, 2026. The filing addresses a significant leadership transition within the company's finance department. The company operates as a remote-first organization without a physical headquarters.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on personnel changes and related compensatory arrangements.
Material Changes
- Departure of CFO: Mr. Peter Kuipers stepped down as Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer effective March 30, 2026.
- Interim CFO Appointment: Mr. Clay Thornton was appointed as Interim Chief Financial Officer and Principal Financial Officer, effective immediately.
- Principal Accounting Officer Appointment: Mr. Joseph (Joe) Oldakowski was appointed as Principal Accounting Officer, effective immediately.
- Severance and Transition: Mr. Kuipers will remain employed for transition services until April 24, 2026, receiving his current base salary and continued equity vesting. He is eligible for severance payments applicable to a termination without cause, contingent upon delivering a general release of claims.
Guidance, Outlook, and Risks
The filing states that Mr. Kuipers' departure does not reflect any disagreement with the Company regarding operations, policies, or practices. No financial guidance, outlook, or new risk factors were disclosed in this report. The new officers, Mr. Thornton and Mr. Oldakowski, are expected to enter into the Company's standard indemnification agreements.
Investor Verification Checklist
- Verify the terms of Mr. Kuipers' employment agreement (Exhibit 10.8 to the 2025 10-K) to confirm specific severance amounts.
- Review the press release (Exhibit 99.1) for additional context on the leadership transition.
- Monitor future filings for the appointment of a permanent Chief Financial Officer.
- Confirm the status of Mr. Kuipers' equity vesting schedule through April 24, 2026.